Thymosin-alpha 1 for Adjuvant Treatment After Radical Resection of High-risk Stage II and III Colorectal Cancer
Condition(s) studied
Investigational drug(s) / intervention(s)
Thymosin Alpha1: Receive thymosin-alpha 1 1.6mg with subcutaneous injection, twice a week, for 6 months after radical resection.
Study summary
For high-risk stage II and stage III colorectal cancer, even after radical resection and postoperative adjuvant chemo/radiotherapy, 30-40% of patients will still have recurrence and metastasis. Thymosin-alpha 1 is believed to improve immunity and may help promote tumor immunity to reduce the incidence of recurrence and metastasis. This study hopes to verify the effecacy and safety of thymosin-alpha 1 for adjuvant treatment of high-risk stage II and stage III colorectal cancer after radical resection.
Eligibility
Primary outcome measure(s)
- 3-year disease-free survival rate — 3 years
percentage of patients who have no recurrence or metastases or death at 3 years after surgery.
Trial sites (1)
| Facility | City | Region | Status |
|---|---|---|---|
| Zhongshan Hospital, Fudan University | Shanghai | Shanghai Municipality | Recruiting |
More Fudan University trials in China
Other trials for the same condition
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT05086614 on ClinicalTrials.gov ↗ ← All trials in China